Investor Relations

Upcoming Events

J.P. Morgan 41st Annual Healthcare Conference

International Stroke Conference 2023

Most Recent Business Quarterly Update

View ReMEDy2 Trial Update

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
301 Carlson Parkway
Suite 210
Minnetonka, MN 55305

Investor Relations

DiaMedica Therapeutics Inc.
Scott Kellen
Chief Financial Officer
T: (763) 496-5192
F: (763) 710-4456
skellen@diamedica.com